Immunotherapy for human cancer using heat shock protein-peptide complexes.
about
Therapeutic cancer vaccines: past, present, and futureThe human HSP70 family of chaperones: where do we stand?Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cellsA heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Stress proteins and initiation of immune response: chaperokine activity of hsp72.Assessment of heat shock protein 70 induction by heat in alfalfa varieties and constitutive overexpression in transgenic plantsHeat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to comeInitiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.Expression of heat shock protein 70 in nasopharyngeal carcinomas: different expression patterns correlate with distinct clinical prognosisTherapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicityA new purification method for enhancing the immunogenicity of heat shock protein 70-peptide complexesPromises and limitations of murine models in the development of anticancer T-cell vaccines.Heat-shock protein-peptide complex-96 for the treatment of cancer.Rebuilding immunity in cancer patients.Vaccine therapy for renal cancer.Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.Cancer immunotherapy by fusions of dendritic cells and tumor cells.The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.An Overview of Biomarkers and Molecular Signatures in HCC.Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?Immunotherapeutic approaches for cancer therapy: An updated review.Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells.Co-inhibition of HSP70/HSP90 synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy.Secretion of the heat shock proteins HSP70 and HSC70 by baby hamster kidney (BHK-21) cells.Expression and purification of recombinant proteins based on human prostate stem cell antigen and heat shock protein-70.Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.Immunomodulatory effects of radiofrequency ablation in a breast cancer model.Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice
P2860
Q26863283-DEB7DDC8-8E2D-47A3-A2DD-C82545A9B342Q28071416-856DE770-FD42-413E-9E09-3A4F29F6C8D7Q33831321-D308E8A4-F852-4167-879A-4A1549D93D99Q34024513-A91D7839-3BA2-4FAE-AD0F-BC1622B57984Q35009889-483EB976-1326-42EB-9A33-2D645AAE5D9DQ35569056-D755C3D0-CE62-49C7-9FB1-24D37354FCC7Q35624485-5DB3DE2A-10A1-4156-9EAA-7294FA1DE8F3Q35624884-DC5AE383-0D74-4379-ABF3-CAA7862D3040Q35792444-3B0FCCA6-E01B-4AA4-8FAE-744699673667Q35900294-F1F67869-FA9F-4C0E-9AB6-77B11F155A61Q36338606-3BE5DB5A-9EAD-4161-8A12-C47C308F7CD3Q36499222-3322341A-401E-48A7-A71E-F894597D9EECQ36525124-7B783941-07B1-4443-8860-A106034A5C42Q36642508-FB13AD56-429D-4A2C-B0BC-833434210B91Q36684482-860436F6-D3E8-4E3C-8053-4D856678764EQ36909395-6CDEFB2D-711E-4DD7-B801-DE4F3A1EBE1FQ36934947-3E1C65E0-C38B-4C22-98EA-56102BEB3C9FQ37259586-20CC32FA-7160-44A9-88CB-926037352DF4Q37383547-2EACE3B4-3F83-4A66-9EA0-D7C25BD16092Q37773276-1DAB8429-11A5-44CD-81C6-CF4AB1E8CBBAQ37908142-DC3663BE-AC4D-4093-8EE2-2B21EB8D1471Q38166571-B40A6274-C813-4796-A169-213FE879FD08Q38222563-3EF3BD87-461F-433B-8DF3-F3A7DD4B6A1BQ38388102-BFD5D84B-F927-455E-B7BB-427D1F3B489AQ38437145-0BA18D0F-5CEA-4006-89A0-3F8564A0365AQ39557740-5002205C-1FA4-4C14-BB0F-AFF822A30495Q39702031-7936BE1D-7524-434C-B912-1F33E13632EBQ39872774-207737E4-1BE3-4142-B6FA-2D3F1672BE50Q41205680-EC768CE7-E51A-4AD2-AA61-901C4C25D973Q43197760-508B9FBC-2FF5-47F2-8EFF-948A32173FC0Q58701885-3089F317-DEAB-47AA-A89F-A8B70A345975
P2860
Immunotherapy for human cancer using heat shock protein-peptide complexes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@ast
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@en
type
label
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@ast
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@en
prefLabel
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@ast
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@en
P2860
P1476
Immunotherapy for human cancer using heat shock protein-peptide complexes.
@en
P2093
Pramod K Srivastava
P2860
P2888
P304
P356
10.1007/S11912-005-0035-8
P577
2005-03-01T00:00:00Z